Successful Oocyte Cryopreservation in Reproductive-Aged Cancer Survivors

Druckenmiller, S.; Goldman, Kara N.; Labella, P.; Fino, Mary Elizabeth; Bazzocchi, Antonia; Noyes, N.

doi:10.1097/aog.0000000000001248

Cited by 53 publications

(37 citation statements)

References 25 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of note, the oldest patient of this cohort (41 years old) cryopreserved 10 oocytes but obtained no euploid embryos after fertilization and did not undergo embryo transfer. In 2016 Druckenmiller et al [69] reported a 44% live birth rate per embryo transfer after thawing/warming of oocytes in 10 patients with a 10 median age of 32 years. Oocyte survival rate and fertilization rate were similar to the ones obtained in patients without cancer at the same institution (live birth rate of 33% in non-cancer patients of less than 43 years).…”

Section: Efficacy Of Oocyte Cryopreservation In Cancer Patientsmentioning

confidence: 99%

State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature

Massarotti

Scaruffi

Lambertini

et al. 2017

Cancer Treatment Reviews

View full text Add to dashboard Cite

During the last decades, important advances in therapeutic options have led to increased survival rates in cancer patients; however, cancer treatments are associated with several potential adverse effects including infertility in those diagnosed during their reproductive years. A proper discussion about fertility preservation options before the use of therapies with potential gonadotoxicity (i.e. oncofertility counseling) is standard of care and should be offered to all patients of childbearing age. Temporary ovarian suppression with LH-RH analogs, oocyte and embryo cryopreservation are standard strategies for fertility preservation in female cancer patients. Oocyte cryopreservation should be preferred to embryo cryopreservation when this latter is prohibited by law, avoided for ethical or religious issues and in single women refusing sperm donation. Despite the increasing use of this strategy, data are still lacking about the efficacy and safety of the procedure in female cancer patients, with most of the evidence on this regard deriving from infertile non-oncologic women. This article aims at critically review the available evidence about the success of oocyte cryopreservation in female cancer patients with the final goal to further improve the oncofertility counseling of these women.

show abstract

Section: Efficacy Of Oocyte Cryopreservation In Cancer Patientsmentioning

confidence: 99%

State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature

Massarotti

Scaruffi

Lambertini

et al. 2017

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

“…Mature oocytes can be effectively cryopreserved using a vitrification method and the success rates of post-thaw fertilization and pregnancy rates have approached those with fresh oocytes in young patients, though success rates with frozen embryos may still be better[46,47]. Oocyte cryopreservation success rates vary depending on age, number of oocytes frozen and the freezing protocol.…”

Section: Fertility Preservation Options For Breast Cancer Patientsmentioning

confidence: 99%

Current state and controversies in fertility preservation in women with breast cancer

Taylan¹,

Oktay²

2017

WJCO

View full text Add to dashboard Cite

On average, over 25000 women are diagnosed with breast cancer under the age of 45 annually in the United States. Because an increasing number of young women delay childbearing to later life for various reasons, a growing population of women experience breast cancer before completing childbearing. In this context, preservation of fertility potential of breast cancer survivors has become an essential concept in modern cancer care. In this review, we will outline the currently available fertility preservation options for women with breast cancer of reproductive age, discuss the controversy behind hormonal suppression for gonadal protection against chemotherapy and highlight the importance of timely referral by cancer care providers.

show abstract

“…Several fertility preservation approaches are available, including cortical or whole ovary cryopreservation and immature oocyte cryopreservation, to store oocytes or embryos for future use (Anderson & Wallace, 2011 (Druckenmiller et al, 2016;Garcia-Velasco et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

“…However currently, embryo and mature oocyte cryopreservation following controlled ovarian stimulation (COS) are the only techniques endorsed by the American Society of Reproductive Medicine with other methods still considered to be investigational (Andersen & Ezcurra, 2014; Ethics Committee of American Society for Reproductive Medicine, 2013). Observational studies reporting on number of oocytes stored for future use have shown satisfactory results (Druckenmiller et al, 2016;Garcia-Velasco et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Ovarian response to controlled ovarian stimulation for fertility preservation before oncology treatment: A retrospective cohort of 157 patients

et al. 2017

View full text Add to dashboard Cite

This is a retrospective cohort study aiming to examine the response of oncology patients undergoing controlled ovarian stimulation (COS) for fertility preservation and to review the incidence of short-term complications. The study group consisted by all oncology patients undergoing ovarian stimulation for fertility preservation (n = 157) between April 2009 and April 2016. Patients undergoing COS for IVF/ICSI for male factor only infertility in the same time period (n = 2,128) provided a comparator group. Oncology patients underwent COS to retrieve eggs for storage and future use. The cancer patients had a very similar distribution of oocyte yield to the comparator group. Those with ovarian cancer did have significantly lower oocyte recovery than those with other cancers (age-adjusted difference 7, 95% CI: 2-12). None of the patients in the study group were admitted with ovarian hyperstimulation syndrome or any other complication of COS or oocyte retrieval. This is one of the largest reported cohorts of patients treated for fertility preservation before oncology treatment. Our data have demonstrated a good response to stimulation, offering a reasonable chance of pregnancy in the future. In contrast to previous studies, we have demonstrated a similar number of oocytes retrieved to that of women undergoing IVF/ICSI treatment for male factor infertility.

show abstract

Successful Oocyte Cryopreservation in Reproductive-Aged Cancer Survivors

Abstract: Oocyte cryopreservation is now a feasible fertility preservation option for reproductive-aged patients with cancer who require gonadotoxic therapies.

Cited by 53 publications

References 25 publications

State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature

State of the art on oocyte cryopreservation in female cancer patients: A critical review of the literature

Current state and controversies in fertility preservation in women with breast cancer

Ovarian response to controlled ovarian stimulation for fertility preservation before oncology treatment: A retrospective cohort of 157 patients

Contact Info

Product

Resources

About